Agoracom Blog

American Creek: $AMK $STNG Stinger Resources Inc. To Commence Trading On Friday March 5th, 2021 $ $ $

Posted by AGORACOM-Eric at 8:47 AM on Thursday, March 4th, 2021
American Creek Provides Update on Its First Quarter Filings

Stinger Resources Inc. (TSX-V: STNG) (the “Company” or “Stinger”) is pleased to announce that it has now received final approval from the TSX Venture Exchange and its common shares will commence trading on Friday, March 5, 2021, under the symbol “STNG”. 
Darren Blaney, Chief Executive Officer of Stinger stated the following: “We are very pleased to have successfully completed this Spinout transaction. We again thank all of the American Creek shareholders for their confidence and support over the years and we look forward to that support continuing to be rewarded as we anticipate the future success of American Creek as well as newly launched Stinger.”
About Stinger Resources Inc.:
Stinger holds interests in gold and silver properties in British Columbia, including the 100% owned past producing Dunwell Mine which is located near Stewart in the prolific “Golden Triangle”.
The Company also holds the D1 McBride project, also located in the “Golden Triangle”.
In addition, Stinger owns the Gold Hill project located near Fort Steele, as well as optioned interests in the Ample Goldmax, Silver Side and Glitter King properties, all of which are located in other prospective areas of the Province of British Columbia.

XPhyto Therapeutics $ $XPHYF Completes Corporate Rebranding and Launches New Website $ $ $ $ $

Posted by AGORACOM-Eric at 8:05 AM on Thursday, March 4th, 2021
  • Rebranding Reflects XPhyto’s Commitment To Operational Achievement
  • Product Development Advance From The Lab To The Clinic
  • Cusp Of Two Major Commercial Milestones Related To Our Rapid Point-Of-Care COVID-19 PCR Test System
  • A Bioscience Accelerator At The Leading-Edge Of The Life Science Industry

XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company has completed a corporate rebranding and launched a new website which can be viewed at

The rebranding decision reflects the Company’s commitment to operational achievement in 2021 as a number of product development programs advance from the laboratory to the clinic. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto is targeting value creation through commercialization of its development pipeline and focused investment in impact driven innovation.

“The Company is excited to introduce a fresh look at such a pivotal point in our business growth,” said Hugh Rogers, CEO & Director of XPhyto. “With all technical requirements fulfilled, we are on the cusp of two major commercial milestones related to our rapid point-of-care COVID-19 PCR test system. With expected ISO certification and CE-IVD approval pending, we are excited to enter the next phase of our business with a positive, crisp and energetic new image.”

The Company will provide further information and updates in due course. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic. Further, its COVID-19 related test products are not yet approved and are still subject to risks associated with the regulatory approval process.

Read More:

VIDEO – AGORACOM Beyond The Expert With Venture Capitalist Leigh Hughes Discusses Small Cap Esports: $GMBL; $FANS / $FUNFF; $TGS; $ITM

Posted by AGORACOM-JC at 5:50 PM on Wednesday, March 3rd, 2021

AGORACOM followers have given us great feedback on our hit series “Beyond The Press Release” (BTPR) in which we speak with small cap CEO’s about important press releases in greater depth and, quite frankly, in layman’s terms for investors to truly understand their significance.

Whereas BTPR tells these stories from the side of small cap public companies, Beyond The Expert (BTE) tells these stories from the perspective of experts on these topics – and we couldn’t think of anyone better to start off this series than Leigh Hughes.

Leigh is a Venture Capitalist who I’ve personally watched conduct incredible due diligence and invest into many small cap companies that have generated incredible returns over 12-18 month periods.  

Leigh is so good at what he does that many global private equity funds and institutions take his call and often follow him into investments he chooses to make.  Moreover, he serves as an advisor to several small cap companies.

If you ever wanted to truly learn how to become a great small cap investor, it doesn’t get much better than this.

On today’s episode we discuss the outlook for esports, why it is so explosive and a few small cap esports companies to consider including:

  • Esports Entertainment Group (GMBL:NASDAQ)
  • FansUnite Entertainment (FANS:CSE / FUNFF:OTCQB)
  • TGS Esports (TGS:TSXV)
  • …. and newcomer Intema Solutions (ITM:TSXV) Who recently completed their acquisition of HypeX

Without further adieu, watch this great interview with Leigh Hughes and make sure to provide us with your feedback via comments on Twitter, YouTube or wherever you may be watching or listening.

VIDEO – Mountain Valley MD $MVMD $MVMDF FDA Application First Step Toward Human Applications For Game Changing Ivectosol™ $CTLT $MRNA $NVAX

Posted by AGORACOM-JC at 5:30 PM on Wednesday, March 3rd, 2021

Mountain Valley MD takes existing Vaccines & Drugs and delivers them better. Into the body better and by transportation. MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications.

To this end they have created Ivectosol™ and it could be a massive disruption in the Vaccine Industry.

If you are looking to learn more about vaccine technologies. This video is a must watch with Dennis Hancock & Mike Farber of MVMD.

See how Mountain Valley MD is doing more with less. 

Quizam Media Corp $ $QQQFF is Seeing Explosive Growth for its Quantum #Cannabis Corporation, Expanding its Retail Footprint amidst The Great Cannabis Gold Rush $FAF $ $CLIQ $ISH $ $

Posted by AGORACOM-JC at 5:01 PM on Wednesday, March 3rd, 2021

Quizam Media Corp’s (QQ:CSE QQQFF:OTC) wholly owned subsidiary Quantum 1 Cannabis is experiencing rapid growth across British Columbia!

In the past 12 months, Quantum 1 has opened stores in:

  • North Vancouver
  • Vernon
  • Grand Forks
  • Keremeos
  • Creston

And it will soon be opening its sixth, and flagship, store in Oakridge, B.C.

In Tandem with this expansion, quarterly revenue is accelerating rapidly, rising from $138,000 in Nov 2019 to $954,000 in Nov 2020.

What’s its secret sauce? The company places a huge emphasis on education. That’s because Quizam has its roots as an educational media company that spent a long time educating people about cannabis, long before it became legal.

  • In this nascent market, people are looking for trusted, authoritative voices

The company’s growth comes as Canada is experiencing ‘The Great Cannabis Gold Rush’ –

  • By 2021, Canada’s cannabis market is expected to reach $3bn, translating to 77.9% CAGR from 2018-2021.
  • Cannabis now contributes $14.6bn to Canada’s economy, up from $8bn previous est.
  • Cannabis 2.0 new products (candy, drinks) could generate $2.5bn in sales in Canada.
  • You’re going to want to get comfy for this conversation with Russ Rossi, Quizam Media’s President & CEO:

VIDEO – Victory Square Technologies $ $VSQTF Portfolio of Companies are Targeting the Future of Borderless, Disruptive Tech, from #Blockchain, #AI and #Robotics, to DNA Sequencing and Energy Storage $ $ $ $

Posted by AGORACOM-JC at 4:14 PM on Wednesday, March 3rd, 2021

Victory Square Technologies (VST:CSE VSQTF:OTC 6F6:FWB) is firing on all cylinders!

The pioneering company, focused on the cutting-edge tech that’s shaping the Fourth Industrial Revolution, has had an explosion of developments for its portfolio companies since sitting down to speak with us last week, including:

As VST CEO Shafin Diamond Tejani discussed in his previous video, the company focuses on building, acquiring and investing in promising start-ups, before providing them with the senior leadership and resources needed for fast-track growth. 

The core of $’s offering centres on five pillars of potential future growth:

  • DNA Sequencing
  • Energy Storage
  • Blockchain
  • Artificial Intelligence
  • Robotics

“Technology is borderless,” says Tejani, as he breaks down the most recent key developments in this must-watch interview with Agoracom:

Red Light Holland $ $TRUFF Red Light Holland’s iMicro Digital Care App Launches Virtual Telecounseling $ $PSYC $FTRP $BUZZ

Posted by AGORACOM-Eric at 10:03 AM on Wednesday, March 3rd, 2021

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company”) is pleased to announce the launch of its Virtual Telecounseling membership program on the Company’s iMicrodose Digital Care App in the Netherlands. The app currently in use by consumers, is accessible from phones, tablets or computers. The telecounseling membership program will be seamlessly integrated into the privacy first iMicro Digital Care web app creating a new frontier for virtual psychedelic platforms. Online support will be offered to adults exploring microdosing with iMicrodose packs powered by Red Light Holland in the Netherlands. Members will be able to approve and share their iMicro Digital Care app data and connect with Red Light Holland’s certified therapist and microdosing expert, Jeff Hamburg, who will provide live virtual telecounseling. Adults can now register to the membership program by going to

“Red Light Holland is extremely proud to introduce virtual telecounseling, the use of digital information and communication technologies to help support the microdosing community. This is just another example of how we are promoting responsible use of our iMicrodose packs. This membership program will bring expert knowledge to the people in the Netherlands,” said Red Light Holland CEO and Director, Todd Shapiro. “I’m excited to have an experienced counselor like Jeff Hamburg connect with Red Light Holland consumers via telecounseling facilitating growth and wellbeing.”

“It’s thrilling to work with Red Light Holland, a company that is immediately building support structures for their customers. I’m excited to be able to offer my experience and knowledge on their consumer’s microdosing journey virtually through telecounseling on the iMicro Digital Care app,” said therapist and microdosing expert Jeff Hamburg.

The company will be offering two tiers of 3 month memberships:

(i) Growth Membership, priced at 75 euro: Includes bi-monthly online support group sessions led by Jeff Hamburg, textual consultation through the iMicro app, a monthly microdosing and creativity event as well as discounts and unique benefits for purchasing Red Light Holland merchandise.

(ii) Transform Membership, currently priced at a rate of 225 euro: For those who are interested in more personal one on one counseling with Jeff Hamburg. The transform membership will include 5 hour private sessions along with all benefits of the Growth membership.

Jeff Hamburg will also be offering short consultations for adults in the Netherlands curious to learn more about microdosing. Adults can register to the membership program or book a free consultation by going to

Read More:

Royal Helium $ Announces Production Testing Underway at Climax-1 and Climax-2 $ $APD $AHELF

Posted by AGORACOM-Eric at 9:58 AM on Wednesday, March 3rd, 2021

Royal Helium Ltd. (“Royal” or the “Company”) (TSXV: RHC) announces that it has engaged two service rigs and that the completions and testing program has been initiated at Climax-1 and Climax-2.  The finalized testing program, which was developed in concert with Sproul Associates Ltd., involves the sequential perforation and gas flow testing of several separate intervals identified during drilling.  Finalized results from the testing program will be reported as the information becomes available.

Royal further announces that the Climax-3 helium well has been drilled to its target depth of 2,600 metres.  Royal’s completion team is reviewing the log data at Climax-3 to determine the intervals to be production tested. The completion and testing program at Climax-3 will commence once testing is complete on Climax-2. 

Andrew Davidson, President and CEO of Royal comments, “We are pleased to have our initial 3 wells at Climax drilled to target depth and we are excited to be production testing these high value targets. We want to thank the team from Savanna 419 for their diligent work in completing this drilling program safely and effectively”. 

Mr. Davidson continues “With 2 service rigs operating we anticipate the testing to be completed on all 3 wells over the next few weeks. While any significant developments will be announced as they are received, all results will be evaluated by Sproule for a potential helium resource and production over multiple separate zones within this large structural closure”.

The three Climax wells were drilled into the Precambrian basement, directly below the Deadwood Formation. The Deadwood is a sand and shale sequence that is a known helium production zone in Saskatchewan. These first three wells are targeting different parts of the same large structural trap identified on the central portion of the Climax land block.

Read More:

Mountain Valley MD $MVMD $MVMDF Proceeding with FDA Pathway Application for Novel Ivectosol™ $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 9:54 AM on Wednesday, March 3rd, 2021
This image has an empty alt attribute; its file name is MVMD-Small.png

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it has contracted Camargo Pharmaceutical Services, LLC (“Camargo”) to provide regulatory consulting services to support MVMD’s pursuit of U.S. Food and Drug Administration (FDA) approval of its novel Ivectosol™ rapid dissolve oral format.

Camargo is recognized as one of the most experienced global organizations who specialize in drug and combination device product development and approval utilizing the regulatory pathway provided for in Section 505(b)(2) of the US Federal Food, Drug, and Cosmetic Act.  Over the last decade, Camargo has established a leading track record with 505(b)(2) investigational new drug (“IND”) and new drug applications (“NDA” preparations and submissions, including participation in more than 1100 Agency meetings and more than 200 FDA NDA and ANDA (Abbreviated New Drug Applications) approvals.

“After successful pre-clinical studies of our novel solubilized Ivectosol™ sublingual in our pre-clinical trials, this is a critical next step in the approval process to support our human application objectives,” stated Mike Farber, Director of Life Sciences at Mountain Valley MD.   “Camargo will be a great partner to accelerate our efforts for the initial pre-IND presentation to the FDA outlining Ivermectin’s prior usage history and extensive safety record for the FDA’s assessment and approval pathway.”

The 505(b)(2) new drug application is one of three U.S. Food and Drug Administration drug approval pathways and represents an appealing regulatory strategy by way of helping to avoid unnecessary duplication of studies already performed on a previously approved drug.  The Company believes the 505(b)(2) pathway will result in a much less expensive and much faster route to approval, compared with a traditional development pathway, while creating a new, differentiated Ivermectin product with tremendous commercial value.

“Camargo is proud to partner with Mountain Valley MD to advance their novel solubilized Ivermectin sublingual wafer,” said Catherine Gatza, PhD, Vice President, Regulatory and Strategy at Camargo. “This program delivers important advantages to the parasitic infection treatment landscape by providing an alternative dosage form.”

As previously communicated, MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity.

“The U.S. FDA approval would prove the efficacy and safety of MVMD’s Ivectosol™ wafer at one of the highest standards in the world and would assist in facilitating greater access to key global markets in an accelerated capacity,” stated Dennis Hancock, President & CEO of Mountain Valley MD.  “The human approval pathway timed with our aggressive pursuit of husbandry applications, is core to making our Ivectosol™ products the number one commercial form of Ivermectin in the world.”

Read More:

ImagineAR $ $IPNFF Awarded US Patent Focused on Location-Based Virtual Gameplay $ $ $ $

Posted by AGORACOM-JC at 9:08 AM on Wednesday, March 3rd, 2021
  • Announced it has been awarded patent number US10,946,284 by the United States Patent and Trademark Office (USPTO).
  • The patent, titled “Systems and Methods for Capture and Use of Local Elements in Gameplay,” adds to ImagineAR’s deep intellectual property portfolio and is focused on location-based virtual gameplay.
  • Patent was developed with a focus on creating a rich multi-player gaming experience where aspects of gameplay may change based on the geographic location of other players as they join and leave the game.

VANCOUVER , BC and ERIE, Pa. , March 3, 2021 /- ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality company that enables sports teams, entertainers, brands and businesses to instantly create immersive global mobile phone AR campaigns, is proud to announce it has been awarded patent number US10,946,284 by the United States Patent and Trademark Office (USPTO). The patent, titled “Systems and Methods for Capture and Use of Local Elements in Gameplay,” adds to ImagineAR’s deep intellectual property portfolio and is focused on location-based virtual gameplay.

The patent was developed with a focus on creating a rich multi-player gaming experience where aspects of gameplay may change based on the geographic location of other players as they join and leave the game. The invention can utilize mobile devices with location sensing capabilities, such as GPS.

ImagineAR CEO, Alen Paul Silverrstieen, stated “This newly approved US patent, in addition to our existing portfolio of five patents, further demonstrates the advanced technology and market leadership of ImagineAR in the North American Augmented Reality marketplace.”

ImagineAR was represented before the USPTO by White and Williams LLP attorney Frank Bruno .

Read More: